Description: Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Home Page: www.zealandpharma.com
Sydmarken 11
Copenhagen,
2860
Denmark
Phone:
45 88 77 36 00
Officers
Name | Title |
---|---|
Mr. Adam Sinding Steensberg M.D. | Pres & CEO |
Ms. Henriette Wennicke | Chief Financial Officer |
Mr. Ivan Mourits Moller | Chief Operating Officer |
Lani Pollworth Morvan | Investor Relations & Communications Officer |
Mr. Mads Kronborg | Head of Investor Relations & Communication |
Mr. Ravinder Chahil | Sr. VP & Gen. Counsel |
Ms. Christina Sonnenborg Bredal | Sr. VP and Global Head of People & Organization |
Ms. Hanne Heidenheim Bak | Sr. Project Director, R&D Operations Mang. and Employee Representative Director |
Dr. Jens Damsgaard Mikkelsen M.D. | Head of Molecular Pharmacology |
Dr. Danilo Verge | Head of Global Medical Affairs |
Exchange: CO
Country: DK
Currency: Danish krone (kr)
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 27.7732 |
Price-to-Sales TTM: | 36.7281 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 203 |